<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368848</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_NSCLC 1</org_study_id>
    <secondary_id>2008-000765-33</secondary_id>
    <nct_id>NCT01368848</nct_id>
  </id_info>
  <brief_title>Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)</brief_title>
  <official_title>Phase II Study to Investigate the Treatment of Patients With NSCLC Stage IIIB and IV Without the Option of Surgery With a Combination of Cisplatin, Docetaxel and Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite recent advances in the treatment of NSCLC overall survival within these patients
      remains dismal and there is yet an unmet medical need for additional treatment options. In
      this phase II study a combination of chemotherapy with an antibody (cisplatin, docetaxel and
      bevacizumab) is tested to determine the objective response rate in patients with unresectable
      and advanced non-small cell lung cancer. This response rate will be compared with historical
      data.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 years</time_frame>
    <description>The primary objective of this proof-of-concept study is to determine the objective response rate in patients with unresectable, stage IIIB and IV non-small cell lung carcinoma treated with the combination cisplatin, docetaxel and bevacizumab. This response rate will be compared to historical data from the ECOG4599 and AVAiL trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression free survival, defined as the duration of time from first study treatment until progression or death from any cause as documented by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival, defined as the duration of time from first study treatment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years</time_frame>
    <description>Duration of response defined as timeframe from first response (CR or PR) until progression from best response.</description>
  </secondary_outcome>
  <enrollment type="Actual">7</enrollment>
  <condition>NSCLC</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -&gt; Staging
-&gt; further 3 cycles BCD Q3W -&gt; Bevacizumab Q3W until progression</description>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -&gt; Staging
-&gt; further 3 cycles BCD Q3W</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -&gt; Staging
-&gt; further 3 cycles BCD Q3W</description>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented inoperable, locally advanced, metastatic or
             recurrent NSCLC other than squamous cell

          -  At least 1 measurable lesion according to RECIST criteria

          -  ECOG performance score 0 or 1

          -  Age between 18 and 70 years

        Exclusion Criteria:

          -  Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a
             predominant squamous component.

          -  History of haemoptysis

          -  Evidence of tumour invading major blood vessels on imaging.

          -  Previous neoadjuvant/adjuvant chemotherapy.

          -  Previous radiotherapy.

          -  Serious uncontrolled coagulation disorder or thrombo-embolic complications within 6
             months prior to study start or history of serious bleeding complications.

          -  Major surgical procedures within 4 weeks prior to study entry.

          -  Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to
             the first bevacizumab infusion.

          -  Non-healing wound, active peptic ulcer or bone fracture.

          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 months of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ.-Klinik für Innere Medizin V Innsbruck, Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6806</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik der PMU Salzburg, UK f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AGMT</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Taxotere</keyword>
  <keyword>Inoperable</keyword>
  <keyword>stages IIIB and IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

